- Conditions
- Hepatic Impairment
- Interventions
- obeticholic acid 10 mg
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Liver Cirrhosis, Biliary
- Interventions
- Placebo, Obeticholic Acid (OCA)
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Houston, Texas • Richmond, Virginia + 1 more
- Conditions
- Dermatitis
- Interventions
- Artificial Fecal Insult, Phosphate Buffered Saline
- Other
- Lead sponsor
- Kimberly-Clark Corporation
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Irving, Texas
- Conditions
- Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80
- Interventions
- pravastatin and chenodeoxycholic acid, after metformin and placebo, valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Obeticholic Acid (OCA), Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 15
- States / cities
- Sacramento, California • San Diego, California • Aurora, Colorado + 11 more
- Conditions
- Cerebrotendinous Xanthomatosis
- Interventions
- chenodeoxycholic acid, lovastatin
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 0 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
- Interventions
- CAP-1002, Placebo
- Biological · Drug
- Lead sponsor
- Capricor Inc.
- Industry
- Eligibility
- 10 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Sacramento, California • Aurora, Colorado • Orlando, Florida + 6 more
- Conditions
- Cerebrotendinous Xanthomatosis
- Interventions
- Chenodeoxycholic Acid
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 5 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 1
- States / cities
- East Orange, New Jersey
- Conditions
- Covid19
- Interventions
- CAP-1002, Placebo
- Biological
- Lead sponsor
- Capricor Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Sacramento, California • Detroit, Michigan + 1 more
- Conditions
- CTX
- Interventions
- Blinded CDCA 250 mg TID, Placebo, Open-Label CDCA 250 mg TID, Rescue Medication CDCA 250 mg TID, CDCA Weight-Based Dose TID
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
- Conditions
- Healthy
- Interventions
- OCA 5 mg, OCA 10 mg, OCA 25 mg
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Healthy
- Interventions
- OCA 10 mg, OCA 25 mg
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Liver Cirrhosis, Biliary
- Interventions
- INT-747, Ursodeoxycholic Acid (URSO), Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 13
- States / cities
- Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Obeticholic Acid
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- La Jolla, California • Sacramento, California • Miami, Florida + 4 more
- Conditions
- Constipation-predominant Irritable Bowel Syndrome
- Interventions
- Sodium chenodeoxycholate (NaCDC), Placebo
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy
- Interventions
- Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic), Sphingomyelin, C13 Stable isotope of Cholesterol
- Dietary Supplement · Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio